• First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to date in this clinical trial
• RECCE^® 327 a(R327) tested at four fast IV infusion times (15-mins, 20-mins, 30-mins, 45-mins) over various dosage levels
• Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples, a dose optimization exercise for regulatory purposes

Recce Pharmaceuticals the Company developing a new class of synthetic anti-infectives, today announced it dosed the first male and female participants at 4,000mg over 20 minutes in the next cohort of a Phase I/II urinary tract infection/urosepsis trial, evaluating its lead candidate, RECCE^® 327 (R327).

The Company has explored multiple infusion times of R327 within this study, ranging from 15-45 minutes. 4,000mg is the highest dose tested in participants in this trial. With Minimum Inhibitory Concentration (MIC) activity against bacteria already detected in existing clinical samples, increasing dose optimization becomes a pivotal exercise for regulatory compliance.

The full efficacious potential of R327 via intravenous (IV) administration will be made available at the completion of this trial in line with the study protocol.